STAAR Surgical Co

STAA is in a sustained medium- and long-term downtrend under a Stage 4 decline. A decisive Support Failure breakdown confirms continued supply dominance. Price is extended below major EMAs in extreme oversold territory, leaving short-term timing unclear. Execution should be deferred, awaiting a failed relief rally into the EMA zone before engaging further.

• ↑Q1 net sales $93.5M (+119.6% YoY) driven by China and Americas
• ↑Q1 adjusted EBITDA $24.4M, swinging from a $26.4M loss last year
• ↓China Q1 sales collapsed to $389K from $38.5M YoY, highlighting market risk